Systemic Artery Vasoconstrictor Therapy in Fontan Patients with High Cardiac Output-Heart Failure: A Single-Center Experience.


Journal

Pediatric cardiology
ISSN: 1432-1971
Titre abrégé: Pediatr Cardiol
Pays: United States
ID NLM: 8003849

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 15 08 2020
accepted: 23 12 2020
pubmed: 9 1 2021
medline: 27 5 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Failed Fontan Patients with high cardiac output (CO) heart failure (HF) might have vasodilatory syndrome and markedly high mortality rates. The aim of this study was to review the clinical effects of vasoconstrictor therapy (VCT) for failed Fontan hemodynamics. We retrospectively reviewed 10 consecutive patients with Fontan failure (median age, 33 years) and high CO-HF who had received VCT. The hemodynamics were characterized by high central venous pressure (CVP: median, 16 mm Hg), low systolic blood pressure (median, 83 mm Hg), low systemic vascular resistance (median, 8.8 U·m

Identifiants

pubmed: 33416919
doi: 10.1007/s00246-020-02532-7
pii: 10.1007/s00246-020-02532-7
doi:

Substances chimiques

Vasoconstrictor Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-706

Références

d’Udekem Y, Iyengar AJ, Cochrane AD et al (2007) The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 116:157-I164
Ohuchi H, Kagisaki K, Miyazaki A et al (2011) Impact of the evolution of the Fontan operation on early and late mortality: a single-center experience of 405 patients over 3 decades. Ann Thorac Surg 92:1457–1466
doi: 10.1016/j.athoracsur.2011.05.055
Khairy P, Fernandes SM, Mayer JE Jr et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117:85–92
doi: 10.1161/CIRCULATIONAHA.107.738559
Diller GP, Kempny A, Alonso-Gonzalez R et al (2015) Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 132:2118–2125
doi: 10.1161/CIRCULATIONAHA.115.017202
Assenza GE, Graham DA, Landzberg MJ et al (2013) MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart 99:491–496
doi: 10.1136/heartjnl-2012-303347
Pundi K, Pundi KN, Kamath PS et al (2016) Liver disease in patients after the Fontan operation. Am J Cardiol 117:456–460
doi: 10.1016/j.amjcard.2015.11.014
Iwakiri Y, Groszmann RJ (2006) The hyperdynamic circulation of chronic liver disease: from the patient to the molecule. Hepatology 43(Suppl 1):S121–S131
doi: 10.1002/hep.20993
Eelco FM (2016) Wijdicks. Hepatic encephalopathy New Engl J Med 375:1660–1670
doi: 10.1056/NEJMra1600561
Ohuchi H (2017) Where is the “optimal” Fontan hemodynamics? Korean Circ J 47:842–857
doi: 10.4070/kcj.2017.0105
Ohuchi H (2016) Adult patients with Fontan circulation: what we know and how to manage adults with Fontan circulation? J Cardiol 68:181–189
doi: 10.1016/j.jjcc.2016.04.001
Agnoletti G, Gala S, Ferroni F et al (2017) Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg 153:1468–1475
doi: 10.1016/j.jtcvs.2017.01.051
Ohuchi H, Miyazaki A, Negishi J et al (2017) Hemodynamic determinants of mortality after Fontan operation. Am Heart J 189:9–18
doi: 10.1016/j.ahj.2017.03.020
Mori M, Aguirre AJ, Elder RW et al (2014) Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol 35:569–579
doi: 10.1007/s00246-014-0881-y
Hebson CL, McCabe NM, Elder RW et al (2013) Hemodynamic phenotype of the failing Fontan in an adult population. Am J Cardiol 112:1943–1947
doi: 10.1016/j.amjcard.2013.08.023
Waypa GB, Schumacker PT (2010) Hypoxia-induced changes in pulmonary and systemic vascular resistance: where is the O2 sensor? Respir Physiol Neurobiol 174:201–211
doi: 10.1016/j.resp.2010.08.007
Groszmann RJ (1994) Hyperdynamic circulation of liver disease 40 years later pathophysiology and clinical consequences. Hepatology 20:13591363
doi: 10.1002/hep.1840200538
SchrierRW AV, Bernardi M et al (1988) Peripheral arterial vasodilatation hypothesis a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151–1157
doi: 10.1002/hep.1840080532
de Mattos ÁZ, de Mattos AA, Méndez-Sánchez N (2016) Hepatorenal syndrome: current concepts related to diagnosis and management. Ann Hepatol 15:474–481
pubmed: 27236146
Cohn JN (1976) Renal hemodynamic alterations in liver disease. Perspect Nephrol Hypertens 3:234–255
Ferenci P, Lockwood A, Mullen K et al (2002) Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721
doi: 10.1053/jhep.2002.31250
Romero-GomezM BF, Garcia-Valdecasas MS et al (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96:2718–2723
doi: 10.1111/j.1572-0241.2001.04130.x
Wong RJ, Gish RG, Ahmed A (2014) Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl 20:1454–1461
doi: 10.1002/lt.23820

Auteurs

Hikari Miike (H)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Hideo Ohuchi (H)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan. hohuchi@ncvc.go.jp.
Department of Adult Congenital Heart Disease, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan. hohuchi@ncvc.go.jp.

Yosuke Hayama (Y)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Toru Isawa (T)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Heima Sakaguchi (H)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Kenichi Kurosaki (K)

Departments of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Michikazu Nakai (M)

Center for Cerebral and Cardiovascular Center, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH